Results 191 to 200 of about 46,296 (214)
Some of the next articles are maybe not open access.
TGFB1-mediated autophagy facilitates oxaliplatin resistance in stomach adenocarcinoma
Biochemistry and Cell BiologyIncreasing evidence has indicated that transforming growth factor beta 1 (TGFB1) is engaged in tumorigenesis and progression. Nevertheless, the underlying role and mechanism of TGFB1 in stomach adenocarcinoma (STAD) chemotherapy remains unknown. TGFB1 levels in various types of cancers were first analyzed by the TCGA database.
Qihua Xu +7 more
openaire +1 more source
Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer.
Anticancer research, 2012Clinical studies have suggested that the epidermal growth factor receptor (EGFR)-inhibiting antibody cetuximab may have better effect in the third-line treatment of metastatic colorectal cancer, after failure of standard chemotherapy including oxaliplatin, compared to using it up-front in the first line. The reason behind this suggestion is unclear.The
Lars, Ekblad, Anders, Johnsson
openaire +1 more source
Integrative oncology: Addressing the global challenges of cancer prevention and treatment
Ca-A Cancer Journal for Clinicians, 2022Jun J Mao,, Msce +2 more
exaly
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Ca-A Cancer Journal for Clinicians, 2020Aaron J Grossberg +2 more
exaly
Oxaliplatin in resistant colorectal cancer: efficacy predictors
Inpharma Weekly, 2001openaire +1 more source
Oral complications of cancer and cancer therapy
Ca-A Cancer Journal for Clinicians, 2012Joel B Epstein +2 more
exaly
American Cancer Society Head and Neck Cancer Survivorship Care Guideline
Ca-A Cancer Journal for Clinicians, 2016Nader Sadeghi +2 more
exaly